Mucosal healing as a treatment for IBD?

Papi, Claudio; Aratari, Annalisa

doi:10.1586/17474124.2014.902302

Cited by 13 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there is growing evidence that compromised intestinal barrier function plays a critical role in the epithelial damage and perpetuation of mucosal inflammation (inflammatory flares) by the recruitment of leukocytes into the subepithelial space that creates a local milieu enriched in soluble pro-and anti-inflammatory mediators that modulate epithelial barrier function (Gassler et al, 2001;Bruewer et al, 2006;Neurath, 2014). Furthermore, mucosal wound healing that is achieved by collective epithelial cell migration and proliferation is important to restore the epithelial barrier and suppress inflammatory responses (Neurath and Travis, 2012;Papi and Aratari, 2014;Quiros and Nusrat, 2019).…”

Section: Introductionmentioning

confidence: 99%

Desmocollin-2 promotes intestinal mucosal repair by controlling integrin-dependent cell adhesion and migration

Flemming

Luissint

Kusters

et al. 2020

MBoC

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Desmocollin-2 promotes intestinal mucosal repair by controlling integrin-dependent cell adhesion and migration

Flemming

Luissint

Kusters

et al. 2020

MBoC

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Previous studies have revealed that mucosal healing is an important therapeutic goal for successfully treating patients with UC as it may improve patient outcomes, potentially changing the course of the disease by inducing sustained clinical remission and reducing the need for hospitalization and surgery (23)(24)(25). However, as there is no established definition of mucosal healing, and it is difficult to assess the efficacy of various drugs (24). One of the most commonly used definitions of mucosal healing, as stated by the International Organization of Inflammatory Bowel Disease, is the 'absence of friability, blood, erosions, and ulcers in all visualized segments' corresponding to a Mayo Endoscopic sub score between 0 and 1 (26).…”

Section: Discussionmentioning

confidence: 99%

IL-8 and LYPD8 expression levels are associated with the inflammatory response in the colon of patients with ulcerative colitis

et al. 2020

View full text Add to dashboard Cite

Ulcerative colitis (UC) is an idiopathic chronic inflammatory disorder affecting the large intestine, which may involve mucosal degeneration. Glycoproteins, mucin2 (MUC2) and the LY6/PLAUR domain containing 8 (LYPD8) are present on the mucous layer of the colon and can hinder the invasion of bacteria, thus contributing to the prevention of colitis. The present study investigated the expression levels of interleukin-8 (IL-8), MUC2 and LYPD8 on the mucous membranes of patients with UC. A total of 18 patients with UC (6 females and 12 males) were examined. Biopsies of the lesions as well as matching normal membranes were obtained and the mRNA expression levels of IL-8, MUC2 and LYPD8 were compared. LYPD8 expression was downregulated in the lesions and the relapsing-remitting subtype of lesions was associated with higher levels of MUC2 expression compared with single attack and chronic lesions subtypes. A positive correlation between Matts' histopathological grade and IL-8, as well as a negative correlation between Matts' histopathological grade and LYPD8 were observed. The expression levels of LYPD8 were lower in highly active lesions and these levels decreased according to the intensity of the mucosal inflammation. Conversely, an increase in MUC2 expression levels may reflect the recovery of the outer mucus layer in the remission phase. Therefore, the examination of MUC2 and LYPD8 expression levels may be useful indicators of mucosal healing in patients with UC.Abbreviations: UC, ulcerative colitis; MUC2, mucin2; LYPD8, LY6/PLAUR domain containing 8; IL-8, interleukin-8

show abstract

“…Complete endoscopic remission, defined as a Mayo endoscopic subscore = 0, was observed in more than 50% of patients. In recent years, targeting MH is an emerging therapeutic endpoint in the management of UC [ 16 , 30 ]. MH has been associated to a more favourable outcome in terms of reduction of clinical relapse, steroid needs, hospitalizations, colorectal cancer, and surgery [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study

Pugliese

Aratari

Festa

et al. 2018

Gastroenterology Research and Practice

Self Cite

View full text Add to dashboard Cite

Background and Aims Thiopurines are commonly used for treating ulcerative colitis (UC), despite the fact that controlled evidence supporting their efficacy is limited. The aim of this study was to evaluate the long-term outcome of thiopurines as maintenance therapy in a large cohort of UC patients. Methods All UC patients receiving thiopurine monotherapy at three tertiary IBD centers from 1995 to 2015 were identified. The primary endpoint was steroid-free clinical remission. Secondary endpoints were mucosal healing (MH), defined as Mayo endoscopic subscore 0, long-term safety, and predictors of sustained clinical remission. Results We identified 192 patients, contributing a total of 747 person-years of follow-up (median follow-up 36 months, range 1–210 months). Steroid dependency was the most common indication for thiopurine treatment (58%). Steroid-free remission occurred in 45.3% of patients; 36.3% stopped thiopurines because of treatment failure and 18.2% for adverse events or intolerance. The cumulative probability of maintaining steroid-free remission while on thiopurine treatment was 87%, 76%, 67.6%, and 53.4% at 12, 24, 36, and 60 months, respectively. MH occurred in 57.9% of patients after a median of 18 months (range 5–96). No independent predictors of sustained clinical remission could be identified. Conclusions Thiopurines represent an effective and safe long-term maintenance therapy for UC patients.

show abstract

Mucosal healing as a treatment for IBD?

Cited by 13 publications

References 21 publications

Desmocollin-2 promotes intestinal mucosal repair by controlling integrin-dependent cell adhesion and migration

Desmocollin-2 promotes intestinal mucosal repair by controlling integrin-dependent cell adhesion and migration

IL-8 and LYPD8 expression levels are associated with the inflammatory response in the colon of patients with ulcerative colitis

Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study

Contact Info

Product

Resources

About